RecruitingPhase 1NCT05942625

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects

Sponsor

Hansoh BioMedical R&D Company

Enrollment

84 participants

Start Date

May 23, 2023

Study Type

INTERVENTIONAL

Conditions

Focal Segmental Glomerulosclerosis IgA Nephropathy

Summary

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HS-10390 tablet and a drug called Placebo tablet for people with focal segmental glomerulosclerosis and iga nephropathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHS-10390 tablet

Oral administration of specified dose of HS-10390

DRUGPlacebo tablet

Oral administration of matching dose ofplacebo

Locations(1)

Zhongda Hospital, Affiliated to Southeast University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05942625

Related Trials

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

NCT066648141 location

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083296 locations

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT0650070271 locations

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT074983356 locations

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

NCT0726863823 locations